ACXP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Acurx Pharmaceuticals Inc (ACXP) is not a good buy for a beginner, long-term investor at this time. The stock's technical indicators show a bearish trend, financial performance is weak, and there are no strong positive catalysts or trading signals to support a buy decision. Additionally, analysts have lowered the price target and delayed expected FDA approval, which adds uncertainty to the stock's future performance.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 43.375, showing no clear signal. Moving averages are converging, suggesting indecision in the market. The stock is trading near its support level of 3.647, but there is no strong indication of a reversal.
NULL identified. No recent news or significant insider/hedge fund activity. Analysts note that the new open-label Phase 2 trial could provide additional data quicker and cheaper, but this is a long-term prospect.
Financial performance in Q4 2025 showed a significant decline in net income (-43.26% YoY) and EPS (-77.81% YoY). The stock has also experienced a -6.09% regular market change and -1.74% post-market change.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income decline of -43.26% YoY, and an EPS drop of -77.81% YoY. Gross margin remained at 0%. Overall, the financials indicate poor performance and lack of growth.
Alliance Global lowered the price target from $20 to $10 and maintained a Buy rating. However, the delayed FDA approval timeline to 2031 introduces uncertainty, making the stock less attractive for long-term investors.
